TuisQL1A • FRA
add
Quidelortho Corp
Vorige sluiting
€24,20
Dagwisseling
€24,00 - €24,60
Jaarwisseling
€21,20 - €45,40
Markkapitalisasie
1,90 mjd USD
Gemiddelde volume
22,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 692,80 m | -2,56% |
Bedryfskoste | 294,60 m | -8,96% |
Netto inkomste | -12,70 m | 99,26% |
Netto winsgrens | -1,83 | 99,24% |
Wins per aandeel | 0,74 | 68,18% |
EBITDA | 155,80 m | 26,26% |
Effektiewe belastingkoers | -44,32% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 128,00 m | 62,44% |
Totale bates | 6,46 mjd | -3,61% |
Totale aanspreeklikheid | 3,46 mjd | 2,03% |
Totale ekwiteit | 3,00 mjd | — |
Uitstaande aandele | 67,63 m | — |
Prys om te bespreek | 0,55 | — |
Opbrengs op bates | 1,89% | — |
Opbrengs op kapitaal | 2,14% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -12,70 m | 99,26% |
Kontant van bedrywe | 65,60 m | 9 471,43% |
Kontant van beleggings | -56,20 m | -178,22% |
Kontant van finansiering | 17,60 m | 195,14% |
Netto kontantverandering | 28,70 m | 170,86% |
Beskikbare kontantvloei | 51,40 m | 250,18% |
Meer oor
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. Wikipedia
Gestig
1979
Hoofkwartier
Webwerf
Werknemers
6 600
